Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Duality Biotherapeutics, Inc.
映恩生物

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 9606)

VOLUNTARY ANNOUNCEMENT

VOLUNTARY LOCK-UP UNDERTAKING BY DIRECTORS AND SENIOR MANAGEMENT

This announcement is made by Duality Biotherapeutics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The directors (the "**Directors**") and senior management of the Company have full confidence in the long-term value and future development prospects of the Company. The board of directors (the "**Board**") of the Company has been informed that, in light of such confidence, each of the following Directors and members of senior management of the Company has voluntarily undertaken not to initiate or direct any sale or other disposal of shares of the Company (the "**Shares**") that beneficially owned by him or her, directly or indirectly, including any Shares acquired upon the exercise of share options during the lock-up period, for a period of six months starting from October 29, 2026 (i.e. October 29, 2026 to April 28, 2027, both days inclusive):

Name	**Position(s) in the Company**
Dr. ZHU Zhongyuan (朱忠遠)	Chairman of the Board, executive Director and chief executive officer
Mr. ZHANG Shaoren (張韶壬)	Executive Director and chief financial officer
Dr. HUA Haiqing (花海清)	Executive Director, senior vice president and head of drug discovery
Dr. QIU Yang (邱楊)	Chief scientific officer and general manager of Dualitybio Inc.
Dr. MU Hua (牟驊)	Global chief medical officer

Name	Position(s) in the Company
Ms. SI Wen (司文)	Executive director (執行總監) of human resources
Mr. YU Xin (于鑫)	Vice president and head of regulatory affairs
Ms. ZHOU Lan (周嵐)	Vice president of commercial strategy
Ms. YUAN Jiali (袁佳麗)	Vice president, head of legal and compliance and joint company secretary

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Duality Biotherapeutics, Inc.
Dr. ZHU Zhongyuan
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, October 29, 2026

As at the date of this announcement, the Board of the Company comprises (i) Dr. ZHU Zhongyuan, Mr. ZHANG Shaoren and Dr. HUA Haiqing as executive directors; (ii) Mr. CAI Zhiyang and Dr. YU Tao as non-executive directors; and (iii) Mr. XIE Dong, Mr. GAO Fengyong and Ms. CHUAI Shuyin as independent non-executive directors.